The 2016 Guideline for Treatment of Lung Cancer of The Japan Lung Cancer Society recommends testing patients with non-squamous NSCLC for multiple biomarkers, including EGFR gene mutation, ALK fusion, and programmed cell death 1 (PD-L1) expression [10]. The gene discussed is ALK; the disease is lung carcinoma.